Kura Oncology Inc (KURA) - Financial Analysis Review

Summary

Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The companys lead drug candidate, Tipifarnib, an inhibitor of protein farnesylation, is a small molecule that targets oncogenes or signaling pathways that drive cancer growth. Tipifarnib- HRAS Mutant Solid Tumors (HRAS), Tipifarnib- Peripheral T-Cell Lymphoma(PTCL), Tipifarnib- Myelodysplastic Syndromes(MDS) and Tipifarnib- Chronic Myelomonocytic Leukemia(CMML) are into Phase II clinical trials.

GlobalData's Kura Oncology Inc (KURA) - Financial Analysis Review provides a comprehensive insight into the company's history, business structure and operations. The report contains information on the company's key employees, key competitors and major products and services, as well as detailed financial ratios for the last 5 years.

Kura Oncology Inc Key Recent Developments:

Nov 07,2016: Kura Oncology Reports Third Quarter 2016 Financial Results
Aug 10,2016: Kura Oncology Reports Second Quarter 2016 Financial Results
May 11,2016: Kura Oncology Reports First Quarter 2016 Financial Results
Mar 17,2016: Kura Oncology Reports Fourth Quarter and Full Year 2015 Operational and Financial Results
Oct 14,2015: Kura Oncology Appoints Thomas Malley to Board of Directors


This up-to-the-minute company report will help you to formulate strategies to drive your business by enabling you to understand your partners, customers and competitors better.

Scope
- Business description - A detailed description of the company's operations and business divisions.
- Company history - Progression of key events associated with the company.
- Major products and services - A list of major products, services and brands of the company.
- Key competitors - A list of key competitors to the company.
- Key employees - A list of the key executives of the company.
- Executive biographies - A brief summary of the executives' employment history.
- Key operational heads - A list of personnel heading key departments/functions.
- Important locations and subsidiaries - A list of key locations and subsidiaries of the company, including contact details.
- Detailed financial ratios for the past five years - The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods - The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note: Some sections may be missing if data is unavailable for the company.

Reasons to Buy

- Gain key insights into the company for academic or business research purposes. Key elements such as detailed business description and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
- Identify potential customers and suppliers with this report's analysis of the company's business structure, operations, major products and services.
- Examine potential investment and acquisition targets with this report's detailed insight into the company's business, financial and operational performance. Financial ratios presented for major public companies in the report include; revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.